Informace o publikaci

Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events

Autoři	HOLMAN Rury R. HAFFNER Steven M. MCMURRAY John J. BETHEL M. A. HOLZHAUER B. HUA T. A. BELENKOV Y. BOOLELL M. BUSE J. B. BUCKLEY B. M. CHACRA A. R. CHIANG F. T. CHARBONNEL B. CHOW C. C. DAVIES M. J. DEEDWANIA P. DIEM P. EINHORN D. FONSECA V. FULCHER G. R. GACIONG Z. GAZTAMBIDE S. GILES T. HORTON E. ILKOVA H. JENSSEN T. KAHN S. E. KRUM H. LAAKSO M. LEITER L. A. LEVITT N.S. MAREEV V. MARTINEZ F. MASSON C. MAZZONE T. MEANEY E. NESTO R. PAN C. Y. PRAGER R. RAPTIS S. A. RUTTEN G. SANDSTROEM H. SCHAPER F. SCHEEN A. SCHMITZ O. SINAY I. SOŠKA Vladimír STENDER S. TAMAS G. TOGNONI G. TUOMILEHTO J. VILLAMIL A. S. VOZAR J. CALIFF R. M.
Rok publikování	2010
Druh	Článek v odborném periodiku
Časopis / Zdroj	New England Journal of Medicine
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Doi	http://dx.doi.org/10.1056/NEJMoa1001122
Obor	Ostatní obory vnitřního lékařství
Klíčová slova	IMPAIRED GLUCOSE-TOLERANCE; RANDOMIZED CONTROLLED-TRIAL; PHASE INSULIN-SECRETION; 10-YEAR FOLLOW-UP; FASTING GLUCOSE; LIFE-STYLE; PREVENTION; MELLITUS; NIDDM; CLASSIFICATION
Popis	BACKGROUND: The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown. METHODS: In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo, in addition to participation in a lifestyle modification program. We followed the participants for a median of 5.0 years for incident diabetes (and a median of 6.5 years for vital status). We evaluated the effect of nateglinide on the occurrence of three coprimary outcomes: the development of diabetes; a core cardiovascular outcome that was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure; and an extended cardiovascular outcome that was a composite of the individual components of the core composite cardiovascular outcome, hospitalization for unstable angina, or arterial revascularization. RESULTS: After adjustment for multiple testing, nateglinide, as compared with placebo, did not significantly reduce the cumulative incidence of diabetes (36% and 34%, respectively; hazard ratio, 1.07; 95% confidence interval [CI], 1.00 to 1.15; P=0.05), the core composite cardiovascular outcome (7.9% and 8.3%, respectively; hazard ratio, 0.94, 95% CI, 0.82 to 1.09; P=0.43), or the extended composite cardiovascular outcome (14.2% and 15.2%, respectively; hazard ratio, 0.93, 95% CI, 0.83 to 1.03; P=0.16). Nateglinide did, however, increase the risk of hypoglycemia. CONCLUSIONS: Among persons with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors, assignment to nateglinide for 5 years did not reduce the incidence of diabetes or the coprimary composite cardiovascular outcomes.